A detailed history of Goldman Sachs Group Inc transactions in Milestone Pharmaceuticals Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,353,067 shares of MIST stock, worth $1.96 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,353,067
Previous 1,353,067 -0.0%
Holding current value
$1.96 Million
Previous $2.42 Million 26.23%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

SELL
$1.67 - $3.39 $2.01 Million - $4.09 Million
-1,205,657 Reduced 47.12%
1,353,067 $2.26 Million
Q3 2023

May 14, 2024

BUY
$2.68 - $3.69 $3.23 Million - $4.45 Million
1,205,657 Added 89.11%
2,558,724 $7.93 Million
Q3 2023

Nov 14, 2023

BUY
$2.68 - $3.69 $9,211 - $12,682
3,437 Added 0.13%
2,558,724 $7.93 Million
Q2 2023

May 14, 2024

BUY
$2.85 - $4.4 $8,042 - $12,416
2,822 Added 0.11%
2,555,287 $7.28 Million
Q2 2023

Aug 14, 2023

BUY
$2.85 - $4.4 $8,042 - $12,416
2,822 Added 0.11%
2,555,287 $7.28 Million
Q1 2023

May 14, 2024

SELL
$3.14 - $4.2 $297,204 - $397,534
-94,651 Reduced 3.58%
2,552,465 $10.1 Million
Q1 2023

May 11, 2023

SELL
$3.14 - $4.2 $297,204 - $397,534
-94,651 Reduced 3.58%
2,552,465 $10.1 Million
Q4 2022

May 14, 2024

BUY
$3.53 - $9.5 $8.98 Million - $24.2 Million
2,542,619 Added 2433.2%
2,647,116 $10.5 Million
Q4 2022

Feb 13, 2023

BUY
$3.53 - $9.5 $8.98 Million - $24.2 Million
2,542,619 Added 2433.2%
2,647,116 $10.5 Million
Q3 2022

May 14, 2024

BUY
$5.86 - $9.43 $542,008 - $872,208
92,493 Added 770.52%
104,497 $960,000
Q3 2022

Nov 10, 2022

BUY
$5.86 - $9.43 $542,008 - $872,208
92,493 Added 770.52%
104,497 $0
Q2 2022

May 14, 2024

SELL
$5.13 - $7.37 $6.88 Million - $9.88 Million
-1,341,063 Reduced 99.11%
12,004 $74,000
Q3 2021

Nov 10, 2021

BUY
$5.28 - $6.29 $63,381 - $75,505
12,004 New
12,004 $69,000

Others Institutions Holding MIST

About Milestone Pharmaceuticals Inc.


  • Ticker MIST
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,010,900
  • Market Cap $43.5M
  • Description
  • Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II cl...
More about MIST
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.